NCT06448962View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

PHASE3CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

November 22, 2021

Study Completion Date

November 22, 2021

Conditions
Hypertension, EssentialPrimary Hypercholesterolemia
Interventions
DRUG

AD-2021

PO, Once daily(QD), 8weeks

DRUG

AD-2022

PO, Once daily(QD), 8weeks

DRUG

AD-2021 Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-2022 Placebo

PO, Once daily(QD), 8weeks

Trial Locations (1)

Unknown

Yonsei Cardiovascular Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT06448962 - Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 | Biotech Hunter | Biotech Hunter